Resources

​​​​​​​Following a landmark TechBio Week, we reflect with some insights from our flagship conference on the transformative potential for growth of technological advances in the sector.

Results from a US multicenter study presented at CHEST show e-Lung could have sped up Progressive Pulmonary Fibrosis (PPF) diagnosis by up to 21 months

Major 2025 deals from Isomorphic Labs and CHARM Therapeutics validate the sector's maturity as it calls for domestic capital to close the 'scale-up gap.' 

It’s TechBio week and we’re celebrating the UK’s leading role in AI and life sciences with significant investment and interest from global players and our own flagship TechBio UK conference and 2025 report launch. 

Good to see support for BIA agendas in government messaging as we continue to push for pension fund reform, attracting the best global talent, UK manufacturing resilience and addressing the challenges of scaling.

The BIA moves into a new era this week, amidst news from the US on tariffs for UK pharma, UK political party conferences underway and a change in leadership at GSK. It’s full steam ahead for BIA towards a busy Autumn, ensuring that the life science sector stays at the top of the government’s priority list and that our members are represented and connected.

MoU will explore collaborative opportunities in biomedicine, biotechnology and bioinformatics, with a strong emphasis on AI applications.

Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, has garnered widespread media attention1 this week following a renewed focus on the impact of its Brainomix 360 Stroke technology to improve recovery rates for stroke patients.

SeqOne, a pioneer in AI-driven genomic analysis, today announced it has entered into a definitive agreement to acquire Congenica, the UK company spun out of the prestigious Wellcome Sanger Institute.

In the third part of our series on Industrial Strategy, Lewis Miles and Maddie Cass provide a deep dive into the Digital and Technologies Sector Plan, analysing how these policies aim to foster growth in the UK's life sciences and engineering biology sectors. We also look forward to strengthening relations and gaining key insight from our US sister organisation with BIO's upcoming UK visit.

In the third instalment of our updates on new Government policy, Lewis Miles and Maddie Cass from BIA’s Policy and Public Affairs team take a deep dive into the Industrial Strategy and the Digital and Technologies Sector Plan, breaking down the implications for engineering biology and the wider life sciences sector.  

In a shifting global landscape, we break down how the UK's new Trade and National Security strategies aim to future-proof our biotech sector.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, shares the vision of hope witnessed at BIA's recent TechBio X event in Cambridge.

In this blog, Sarah Potter, Partner - Patent Attorney and Robert Cogger-Ward, Associate at Potter Clarkson, share what you need to know about DSI and the Cali Fund.

In this latest white paper, Dave Cooper, Project Pursuit Manager at Emerson, explores how forward-thinking biotech companies can meet the growing demand for personalised treatments by reimagining their manufacturing strategies.

The Data (Use and Access) Act became law last week – but what does it mean for the life science sector? Fredericka Argent, Paul Maynard, and Tom Griffiths from Covington and Burling’s technology regulatory team explain all in this blog.

Brainomix and 3DR Labs announced a new strategic partnership to support acute stroke care in the US through the clinically validated and FDA-cleared Brainomix 360 Stroke.

From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.